Table 1

Demographic, geographical, clinical and laboratory features of patients with SARS-CoV-2 and Guillain-Barré syndrome (GBS)

Number (%)
Number of patients42
Age: years, median (IQR) (range)57.5 (50.7–65.2) (21–77)
Gender: males:females27 (64.3):15 (35.7)
Country
 Italy13 (30.9)
 Spain7 (16.7)
 France5 (11.9)
 USA4 (9.5)
 Switzerland4 (9.5)
 Iran2 (4.8)
 China1 (2.4)
 Canada1 (2.4)
 Germany1 (2.4)
 Turkey1 (2.4)
 Austria1 (2.4)
 The Netherlands1 (2.4)
 UK1 (2.4)
Diagnosis of SARS-CoV-2 infection
 Nasopharyngeal swab positive36 (85.7)
 Serology positive6 (14.3)
Presenting symptoms of COVID-19
 Asymptomatic1 (2.4)
 Oligosymptomatic4 (9.5)
 Fever31 (73.8)
 Cough28 (66.7)
 Dyspnoea7 (16.7)
 Headache5 (11.9)
 Hypoageusia16 (38.0)
 Hypoanosmia11 (26.2)
 Gastrointestinal8 (19.0)
 Myalgia7 (16.7)
Interstitial pneumonia26 (61.9%)
Relationship between onset of COVID-19 and GBS symptoms
 Not reported or not calculable4 (9.5)
 GBS as presenting feature2 (4.8)
 Time interval between onset of COVID-19 and GBS in 36 patients: days, median (IQR) (range)11.5 (7.7–16) (3–28)
 COVID-19 clinically resolved before GBS11 (26.2)